NCT00098761 - VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

February 29, 2008

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

laromustine

This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.

Trial Locations (10)

15213

Children's Hospital of Pittsburgh, Pittsburgh

27710

Duke Comprehensive Cancer Center, Durham

38105

St. Jude Children's Research Hospital, Memphis

60614

Children's Memorial Hospital - Chicago, Chicago

94115

UCSF Comprehensive Cancer Center, San Francisco

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

20010-2970

Children's National Medical Center, Washington D.C.

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

19104-4318

Children's Hospital of Philadelphia, Philadelphia

77030-2399

Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Pediatric Brain Tumor Consortium

NETWORK